New cancer drug karonudib tested for first time in humans
NCT ID NCT03036228
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase trial tested a new drug, Karonudib, in 63 people with advanced solid tumors that had not responded to standard treatments. The main goal was to check the drug's safety and find the best dose. Researchers also looked at how the drug moves through the body and any early signs of tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Karonudib (TH1579)
What this could lead to
If it works, this could point toward a new treatment option for advanced solid tumors.
What could go wrong
This is a very early Phase 1 trial with only 63 participants, focused on safety and dosing. It is not designed to prove effectiveness, and many early cancer drugs fail to show benefit in later trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Karolinska University Hospital
Stockholm, Sweden
-
Sahlgrenska University Hospital
Gothenburg, Sweden
-
Uppsala University Hospital
Uppsala, Sweden